PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine.
Elisa BaldelliK Alex HodgeGuido BellezzaNeil J ShahGuido GambaraAngelo SidoniMartina MandaranoChamodya RuhunusiriBryant DunetzMaysa Abu-KhalafJulia WulfkuhleRosa I GallagherLance LiottaJohann de BonoNiven MehraRuth RiisnaesAntonella RavaggiFranco OdicinoMaria Isabella SereniMatthew BlackburnAngela ZupaGiuseppina ImprotaPerry DemskoLucio Crino'Vienna LudoviniGiuseppe GiacconeEmanuel F PetricoinMariaelena PierobonPublished in: Journal for immunotherapy of cancer (2022)
Continuous RPPA-based measurements capture a broad dynamic range of PD-L1 expression in human specimens and heterogeneous concordance levels between antibody clones. This high throughput immunoassay can potentially identify subgroups of tumors in which low expression of PD-L1 equates to lack of response to treatment.